Drug Profile
Prostate cancer therapy - Advagen
Latest Information Update: 29 Oct 2021
Price :
$50
*
At a glance
- Originator Advagen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
- 13 Feb 2001 Preclinical development for Prostate cancer in USA (Unknown route)